Transfusion support for matched sibling allogeneic hematopoietic stem cell transplantation (1993–2010): factors that predict intensity and time to transfusion independence

Patients undergoing allogeneic hematopoietic stem cell transplant require variable, often extensive transfusion support. Identification of factors that predict urgent, intensive, or special needs should improve management of these patients.

[1]  P. Muranski,et al.  Ex vivo T-cell-depleted allogeneic stem cell transplantation for hematologic malignancies: The search for an optimum transplant T-cell dose and T-cell add-back strategy. , 2017, Cytotherapy.

[2]  D. Allan,et al.  Optimal transfusion practices after allogeneic hematopoietic cell transplantation: a systematic scoping review of evidence from randomized controlled trials , 2016, Transfusion.

[3]  E. Staley,et al.  An update on ABO incompatible hematopoietic progenitor cell transplantation. , 2016, Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis.

[4]  Y. Kfoury,et al.  Hematopoietic Stem Cell Niche in Health and Disease. , 2016, Annual review of pathology.

[5]  M. Patnaik,et al.  ABO blood group incompatibility as an adverse risk factor for outcomes in patients with myelodysplastic syndromes and acute myeloid leukemia undergoing HLA‐matched peripheral blood hematopoietic cell transplantation after reduced‐intensity conditioning , 2016, Transfusion.

[6]  Chang Liu,et al.  Red blood cell transfusion for hematologic disorders. , 2015, Hematology. American Society of Hematology. Education Program.

[7]  D. Purtill,et al.  Red cell and platelet transfusion burden following myeloablative allogeneic haemopoietic stem cell transplantation , 2015, Internal medicine journal.

[8]  S. Datta,et al.  An analysis of transfusion support in haematopoietic stem cell transplantation--report from a centre in India. , 2015, Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis.

[9]  J. Ward,et al.  Impact of ABO blood group mismatch in alemtuzumab-based reduced-intensity conditioned haematopoietic SCT , 2015, Bone Marrow Transplantation.

[10]  S. Morrison,et al.  The bone marrow niche for haematopoietic stem cells , 2014, Nature.

[11]  N. Dunbar,et al.  Transfusion guidelines: when to transfuse. , 2013, Hematology. American Society of Hematology. Education Program.

[12]  S. Steinberg,et al.  Host lymphocyte depletion as a strategy to facilitate early full donor chimerism after reduced-intensity allogeneic stem cell transplantation. , 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[13]  E. Gehrie,et al.  Clinical guide to ABO-incompatible allogeneic stem cell transplantation. , 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[14]  Thomas E. Hughes,et al.  Dose-adjusted EPOCH-rituximab combined with fludarabine provides an effective bridge to reduced-intensity allogeneic hematopoietic stem-cell transplantation in patients with lymphoid malignancies. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  W. Flegel,et al.  Recommendations for transfusion in ABO‐incompatible hematopoietic stem cell transplantation , 2012, Transfusion.

[16]  M. Sorror,et al.  The impact of donor type and ABO incompatibility on transfusion requirements after nonmyeloablative haematopoietic cell transplantation , 2010, British journal of haematology.

[17]  Jonathan D. Powell,et al.  Allogeneic hematopoietic stem-cell transplantation for sickle cell disease. , 2009, The New England journal of medicine.

[18]  W. Berdel,et al.  The influence of blood group differences in allogeneic hematopoietic peripheral blood progenitor cell transplantation , 2005, Transfusion.

[19]  J. P. McCoy,et al.  Persistence of recipient plasma cells and anti‐donor isohaemagglutinins in patients with delayed donor erythropoiesis after major ABO incompatible non‐myeloablative haematopoietic cell transplantation , 2005, British journal of haematology.

[20]  J F Chapman,et al.  Blood inventory management , 2004, Vox sanguinis.

[21]  R. Bouabdallah,et al.  Decreased RBCTs after reduced intensity conditioning allogeneic stem cell transplantation: predictive value of prior Hb level , 2004, Transfusion.

[22]  M. Bishop,et al.  Immunoablative reduced-intensity stem cell transplantation: potential role of donor Th2 and Tc2 cells. , 2004, Seminars in oncology.

[23]  S. Solomon,et al.  The graft-versus-leukemia effect of nonmyeloablative stem cell allografts may not be sufficient to cure chronic myelogenous leukemia , 2003, Bone Marrow Transplantation.

[24]  G. Ruiz-Argüelles,et al.  Decreased Transfusion Requirements in Patients Given Stem Cell Allografts Using a Non-myeloablative Conditioning Regimen: A Single Institution Experience , 2003, Hematology.

[25]  J. Lipton,et al.  RBC transfusion requirements after allogeneic marrow transplantation: impact of the before‐transplant Hb level on transfusion and early survival , 2003, Transfusion.

[26]  R. Storb,et al.  Decreased transfusion requirements for patients receiving nonmyeloablative compared with conventional peripheral blood stem cell transplants from HLA-identical siblings. , 2001, Blood.

[27]  R. Altemus,et al.  Transplant dose of CD34+ and CD3+ cells predicts outcome in patients with haematological malignancies undergoing T cell‐depleted peripheral blood stem cell transplants with delayed donor lymphocyte add‐back , 2001, British journal of haematology.

[28]  A. Barrett,et al.  Delayed donor red cell chimerism and pure red cell aplasia following major ABO-incompatible nonmyeloablative hematopoietic stem cell transplantation. , 2001, Blood.

[29]  S. Holland,et al.  Treatment of chronic granulomatous disease with nonmyeloablative conditioning and a T-cell-depleted hematopoietic allograft. , 2001, The New England journal of medicine.

[30]  A. Barrett,et al.  Massive immune haemolysis after allogeneic peripheral blood stem cell transplantation with minor ABO incompatibility , 2001, British journal of haematology.

[31]  W. Linehan,et al.  Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. , 2000, The New England journal of medicine.

[32]  Young,et al.  CD34+ cell dose predicts relapse and survival after T‐cell‐depleted HLA‐identical haematopoietic stem cell transplantation (HSCT) for haematological malignancies , 2000, British journal of haematology.

[33]  N. Young,et al.  Engraftment kinetics after nonmyeloablative allogeneic peripheral blood stem cell transplantation: full donor T-cell chimerism precedes alloimmune responses. , 1999, Blood.

[34]  J. Fischer,et al.  Toward standardization of CD34+ cell enumeration: an international study , 1999, Transfusion.

[35]  J. Vose,et al.  A multicenter study of platelet recovery and utilization in patients after myeloablative therapy and hematopoietic stem cell transplantation. , 1998, Blood.

[36]  N. Young,et al.  T cell-depleted bone marrow transplantation and delayed T cell add-back to control acute GVHD and conserve a graft-versus-leukemia effect , 1998, Bone Marrow Transplantation.

[37]  A. Raptis,et al.  T cell-depleted granulocyte colony-stimulating factor (G-CSF) modified allogeneic bone marrow transplantation for hematological malignancy improves graft CD34+ cell content but is associated with delayed pancytopenia , 1998, Bone Marrow Transplantation.

[38]  C. Dunbar,et al.  CD34+ cell dose predicts survival, posttransplant morbidity, and rate of hematologic recovery after allogeneic marrow transplants for hematologic malignancies , 1996 .

[39]  D. Sutherland,et al.  The ISHAGE guidelines for CD34+ cell determination by flow cytometry. International Society of Hematotherapy and Graft Engineering. , 1996, Journal of hematotherapy.

[40]  P. Anderson.  Clinical Immunology: Principles and Practice , 1996 .

[41]  N. L. Short.  The Working Party , 1964 .

[42]  D. Scadden,et al.  Hematopoietic Stem Cell and Its Bone Marrow Niche. , 2016, Current topics in developmental biology.

[43]  I. Weissman.  Hematopoietic Stem Cells, Regenerative Medicine, and Leukemogenesis , 2016 .

[44]  M. O'donnell.  Blood Group Incompatibilities and Hemolytic Complications of Hematopoietic Cell Transplantation , 2016 .

[45]  J. M. Cullough.  Principles of Transfusion Support Before and After Hematopoietic Cell Transplantation , 2016 .

[46]  C. Cohn.  Transfusion support issues in hematopoietic stem cell transplantation. , 2015, Cancer control : journal of the Moffitt Cancer Center.

[47]  I. Avonto,et al.  Consequences of ABO incompatibility in multiple myeloma patients undergoing peripheral blood stem cell transplantation after reduced intensity conditioning. , 2011, Blood transfusion = Trasfusione del sangue.

[48]  A. Barrett.  CHAPTER 2 – Essential biology of stem cell transplantation , 2009 .

[49]  A. Barrett,et al.  Hematopoietic stem cell transplantation : in clinical practice , 2009 .

[50]  David R. Criswell,et al.  Recommendations by the , 2000 .